TSLP and systemic sclerosis: Given the critical role of TSLP in the early phases (endothelial injury and autoimmune inflammation) and late phases (fibrosis) of SSc, therapeutically targeted modulation of TSLP may represent a novel antifibrotic strategy in SSc patients and warrants further investigation.